Lower Dopamine Production Tracked With Higher Apathy Scores in Regular Cannabis Users | Research

The takeaway

In 14 regular users, lower striatal dopamine synthesis was linked to higher self-reported apathy, with the strongest link in the brain’s associative striatum.

Readers following the amotivation debate who want neuroimaging data linking apathy scores to dopamine function in regular cannabis users.

-0.69
correlation between associative striatal dopamine synthesis and apathy severity

What the researchers found

Every participant scored above the clinical cutoff for apathy on the Apathy Evaluation Scale. Within this small group, people with lower dopamine synthesis capacity in the striatum reported more apathy. The association was strongest in the associative striatum, a region involved in planning and goal-directed behavior (rho = -0.69, p = 0.006). The whole striatum also showed an inverse link (rho = -0.64, p = 0.015). Limbic and sensorimotor subdivisions did not show significant associations. Apathy scores were not significantly related to current cannabis consumption or age of first use in this sample.

Why it matters

Apathy and reduced drive are common complaints among regular users. The study links apathy severity to a dopamine synthesis marker in brain circuits tied to goal-directed behavior. It does not establish cause, but it maps a specific biological measure to a self-reported motivational state in living humans using a well-validated imaging tool.

The numbers in context

- Sample: 14 regular cannabis users assessed once with [18F]-DOPA PET and an apathy questionnaire

- Apathy scores: median 59.5 on the AES-S (IQR 7.5), well above the clinical cutoff of 34, meaning pronounced apathy in this group

- Dopamine–apathy link, whole striatum: rho = -0.64, p = 0.015, lower dopamine synthesis associated with higher apathy

- Dopamine–apathy link, associative striatum: rho = -0.69, p = 0.006, strongest association observed

How the study worked

This was a cross-sectional imaging study of 14 regular cannabis users. Dopamine synthesis capacity was measured using [18F]-DOPA PET and summarized as K i(cer), an index of how readily the brain synthesizes dopamine using a cerebellar reference. Subjective apathy was measured with the self-rated Apathy Evaluation Scale. Researchers examined Spearman correlations between apathy scores and K i(cer) for the whole striatum and its functional subdivisions: associative, limbic, and sensorimotor. There was no non-user control group and no experimental manipulation.

Who was studied

N=14 regular cannabis users, Country not specified

What this study cannot tell us

Very small sample size (n = 14) limits precision and generalizability. Cross-sectional design cannot determine directionality. No non-user control group, so it is unclear how these values compare to people who do not use cannabis. Apathy was self-rated, which can be influenced by mood and context. Cannabis product types, THC or CBD content, and timing of last use were not reported in the abstract. Null findings in limbic and sensorimotor regions could reflect true specificity or low statistical power.

How to read the evidence

Rated preliminary: single-group, cross-sectional PET study with 14 participants and self-reported apathy. No control group or dose data. Findings are correlational and may not generalize.

When this study was published

Published in 2014. Imaging methods remain relevant, but today’s cannabis products often have different potencies and cannabinoid profiles than a decade ago, which may influence generalizability.

The bigger picture

Debates about an amotivational pattern in cannabis use often rely on self-reports or broad behavioral measures. This study adds a neurochemical datapoint by tying apathy scores to a PET marker of dopamine synthesis in associative striatum, a circuit linked to planning and effort allocation. The absence of a dose or age-of-onset relationship in this small group complicates simple dose–response narratives. Without a control group or longitudinal data, the direction of the link is unresolved. The finding is best viewed as a within-user association that points to specific brain circuitry rather than a proof of cause.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Would the same dopamine–apathy pattern appear when directly compared to a matched non-user group?
Does the association persist, strengthen, or weaken after a period of abstinence?
Are objective effort-based tasks aligned with the self-reported apathy and PET findings?
Do product characteristics, such as THC and CBD ratios, track with dopamine synthesis and apathy?
Is the associative striatum uniquely involved, or would larger samples reveal broader or different regional patterns?

Common questions

What does K i(cer) measure?

It is a PET-derived index of dopamine synthesis capacity. Lower values suggest the brain is producing dopamine less readily in the measured region.

Did heavier current use mean more apathy?

Not in this small sample. Apathy scores were not significantly related to current consumption or age of first use.

Does this prove cannabis causes apathy through dopamine changes?

No. The study shows an association within regular users at a single time point. Without controls or longitudinal data, cause and direction cannot be determined.

Read the original research

The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.

Psychopharmacology, 231(11), 2251-9

Psychopharmacology is a peer-reviewed scientific journal covering the field of psychopharmacology.

View on PubMed ↗Publisher’s paper ↗

Citation

Bloomfield, Michael A P; Morgan, Celia J A; Kapur, Shitij; Curran, H Valerie; Howes, Oliver D. (2014). The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.. Psychopharmacology, 231(11), 2251-9. https://doi.org/10.1007/s00213-014-3523-4